Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies
Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma (MM). Population-based screening for MGUS could identify candidates for early treatment in MM. Here we describe the Iceland Screens, Treats, or Prevents Multiple Myeloma study (iStopMM), the first population-based sc...
Published in: | Blood Cancer Journal |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Text |
Language: | English |
Published: |
Nature Publishing Group UK
2021
|
Subjects: | |
Online Access: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128921/ http://www.ncbi.nlm.nih.gov/pubmed/34001889 https://doi.org/10.1038/s41408-021-00480-w |
id |
ftpubmed:oai:pubmedcentral.nih.gov:8128921 |
---|---|
record_format |
openpolar |
spelling |
ftpubmed:oai:pubmedcentral.nih.gov:8128921 2023-05-15T16:47:57+02:00 Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies Rögnvaldsson, Sæmundur Love, Thorvardur Jon Thorsteinsdottir, Sigrun Reed, Elín Ruth Óskarsson, Jón Þórir Pétursdóttir, Íris Sigurðardóttir, Guðrún Ásta Viðarsson, Brynjar Önundarson, Páll Torfi Agnarsson, Bjarni A. Sigurðardóttir, Margrét Þorsteinsdóttir, Ingunn Ólafsson, Ísleifur Þórðardóttir, Ásdís Rósa Eyþórsson, Elías Jónsson, Ásbjörn Björnsson, Andri S. Gunnarsson, Gunnar Þór Pálsson, Runólfur Indriðason, Ólafur Skúli Gíslason, Gauti Kjartan Ólafsson, Andri Hákonardóttir, Guðlaug Katrín Brinkhuis, Manje Halldórsdóttir, Sara Lovísa Ásgeirsdóttir, Tinna Laufey Steingrímsdóttir, Hlíf Danielsen, Ragnar Dröfn Wessman, Inga Kampanis, Petros Hulcrantz, Malin Durie, Brian G. M. Harding, Stephen Landgren, Ola Kristinsson, Sigurður Yngvi 2021-05-17 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128921/ http://www.ncbi.nlm.nih.gov/pubmed/34001889 https://doi.org/10.1038/s41408-021-00480-w en eng Nature Publishing Group UK http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128921/ http://www.ncbi.nlm.nih.gov/pubmed/34001889 http://dx.doi.org/10.1038/s41408-021-00480-w © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . CC-BY Blood Cancer J Article Text 2021 ftpubmed https://doi.org/10.1038/s41408-021-00480-w 2021-05-30T00:29:10Z Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma (MM). Population-based screening for MGUS could identify candidates for early treatment in MM. Here we describe the Iceland Screens, Treats, or Prevents Multiple Myeloma study (iStopMM), the first population-based screening study for MGUS including a randomized trial of follow-up strategies. Icelandic residents born before 1976 were offered participation. Blood samples are collected alongside blood sampling in the Icelandic healthcare system. Participants with MGUS are randomized to three study arms. Arm 1 is not contacted, arm 2 follows current guidelines, and arm 3 follows a more intensive strategy. Participants who progress are offered early treatment. Samples are collected longitudinally from arms 2 and 3 for the study biobank. All participants repeatedly answer questionnaires on various exposures and outcomes including quality of life and psychiatric health. National registries on health are cross-linked to all participants. Of the 148,704 individuals in the target population, 80 759 (54.3%) provided informed consent for participation. With a very high participation rate, the data from the iStopMM study will answer important questions on MGUS, including potentials harms and benefits of screening. The study can lead to a paradigm shift in MM therapy towards screening and early therapy. Text Iceland PubMed Central (PMC) Blood Cancer Journal 11 5 |
institution |
Open Polar |
collection |
PubMed Central (PMC) |
op_collection_id |
ftpubmed |
language |
English |
topic |
Article |
spellingShingle |
Article Rögnvaldsson, Sæmundur Love, Thorvardur Jon Thorsteinsdottir, Sigrun Reed, Elín Ruth Óskarsson, Jón Þórir Pétursdóttir, Íris Sigurðardóttir, Guðrún Ásta Viðarsson, Brynjar Önundarson, Páll Torfi Agnarsson, Bjarni A. Sigurðardóttir, Margrét Þorsteinsdóttir, Ingunn Ólafsson, Ísleifur Þórðardóttir, Ásdís Rósa Eyþórsson, Elías Jónsson, Ásbjörn Björnsson, Andri S. Gunnarsson, Gunnar Þór Pálsson, Runólfur Indriðason, Ólafur Skúli Gíslason, Gauti Kjartan Ólafsson, Andri Hákonardóttir, Guðlaug Katrín Brinkhuis, Manje Halldórsdóttir, Sara Lovísa Ásgeirsdóttir, Tinna Laufey Steingrímsdóttir, Hlíf Danielsen, Ragnar Dröfn Wessman, Inga Kampanis, Petros Hulcrantz, Malin Durie, Brian G. M. Harding, Stephen Landgren, Ola Kristinsson, Sigurður Yngvi Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies |
topic_facet |
Article |
description |
Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma (MM). Population-based screening for MGUS could identify candidates for early treatment in MM. Here we describe the Iceland Screens, Treats, or Prevents Multiple Myeloma study (iStopMM), the first population-based screening study for MGUS including a randomized trial of follow-up strategies. Icelandic residents born before 1976 were offered participation. Blood samples are collected alongside blood sampling in the Icelandic healthcare system. Participants with MGUS are randomized to three study arms. Arm 1 is not contacted, arm 2 follows current guidelines, and arm 3 follows a more intensive strategy. Participants who progress are offered early treatment. Samples are collected longitudinally from arms 2 and 3 for the study biobank. All participants repeatedly answer questionnaires on various exposures and outcomes including quality of life and psychiatric health. National registries on health are cross-linked to all participants. Of the 148,704 individuals in the target population, 80 759 (54.3%) provided informed consent for participation. With a very high participation rate, the data from the iStopMM study will answer important questions on MGUS, including potentials harms and benefits of screening. The study can lead to a paradigm shift in MM therapy towards screening and early therapy. |
format |
Text |
author |
Rögnvaldsson, Sæmundur Love, Thorvardur Jon Thorsteinsdottir, Sigrun Reed, Elín Ruth Óskarsson, Jón Þórir Pétursdóttir, Íris Sigurðardóttir, Guðrún Ásta Viðarsson, Brynjar Önundarson, Páll Torfi Agnarsson, Bjarni A. Sigurðardóttir, Margrét Þorsteinsdóttir, Ingunn Ólafsson, Ísleifur Þórðardóttir, Ásdís Rósa Eyþórsson, Elías Jónsson, Ásbjörn Björnsson, Andri S. Gunnarsson, Gunnar Þór Pálsson, Runólfur Indriðason, Ólafur Skúli Gíslason, Gauti Kjartan Ólafsson, Andri Hákonardóttir, Guðlaug Katrín Brinkhuis, Manje Halldórsdóttir, Sara Lovísa Ásgeirsdóttir, Tinna Laufey Steingrímsdóttir, Hlíf Danielsen, Ragnar Dröfn Wessman, Inga Kampanis, Petros Hulcrantz, Malin Durie, Brian G. M. Harding, Stephen Landgren, Ola Kristinsson, Sigurður Yngvi |
author_facet |
Rögnvaldsson, Sæmundur Love, Thorvardur Jon Thorsteinsdottir, Sigrun Reed, Elín Ruth Óskarsson, Jón Þórir Pétursdóttir, Íris Sigurðardóttir, Guðrún Ásta Viðarsson, Brynjar Önundarson, Páll Torfi Agnarsson, Bjarni A. Sigurðardóttir, Margrét Þorsteinsdóttir, Ingunn Ólafsson, Ísleifur Þórðardóttir, Ásdís Rósa Eyþórsson, Elías Jónsson, Ásbjörn Björnsson, Andri S. Gunnarsson, Gunnar Þór Pálsson, Runólfur Indriðason, Ólafur Skúli Gíslason, Gauti Kjartan Ólafsson, Andri Hákonardóttir, Guðlaug Katrín Brinkhuis, Manje Halldórsdóttir, Sara Lovísa Ásgeirsdóttir, Tinna Laufey Steingrímsdóttir, Hlíf Danielsen, Ragnar Dröfn Wessman, Inga Kampanis, Petros Hulcrantz, Malin Durie, Brian G. M. Harding, Stephen Landgren, Ola Kristinsson, Sigurður Yngvi |
author_sort |
Rögnvaldsson, Sæmundur |
title |
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies |
title_short |
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies |
title_full |
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies |
title_fullStr |
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies |
title_full_unstemmed |
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies |
title_sort |
iceland screens, treats, or prevents multiple myeloma (istopmm): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies |
publisher |
Nature Publishing Group UK |
publishDate |
2021 |
url |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128921/ http://www.ncbi.nlm.nih.gov/pubmed/34001889 https://doi.org/10.1038/s41408-021-00480-w |
genre |
Iceland |
genre_facet |
Iceland |
op_source |
Blood Cancer J |
op_relation |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128921/ http://www.ncbi.nlm.nih.gov/pubmed/34001889 http://dx.doi.org/10.1038/s41408-021-00480-w |
op_rights |
© The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
op_rightsnorm |
CC-BY |
op_doi |
https://doi.org/10.1038/s41408-021-00480-w |
container_title |
Blood Cancer Journal |
container_volume |
11 |
container_issue |
5 |
_version_ |
1766038051164782592 |